Makaryan V, Kelley M, Bolyard A, Chugh G, Dale D
J Cell Immunol. 2025; 6(5):211-218.
PMID: 39867870
PMC: 11759478.
DOI: 10.33696/immunology.6.208.
Watt S, Roubelakis M
Int J Mol Sci. 2025; 26(2).
PMID: 39859383
PMC: 11766050.
DOI: 10.3390/ijms26020671.
Dascalu M, Daraban Bocaneti F, Soreanu O, Tutu P, Cozma A, Morosan S
Animals (Basel). 2025; 14(24.
PMID: 39765486
PMC: 11672453.
DOI: 10.3390/ani14243582.
Xu Y, Huang L, Wang J, He J, Wang Y, Zhang W
BMC Cancer. 2024; 24(1):1387.
PMID: 39533204
PMC: 11556076.
DOI: 10.1186/s12885-024-13156-y.
Abdalsada H, Abdulsaheb Y, Zolghadri S, Al-Hakeim H, Stanek A
Biomedicines. 2024; 12(9).
PMID: 39335530
PMC: 11428511.
DOI: 10.3390/biomedicines12092015.
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.
Zhang Q, Wang Z, Yao W, Wang S, Zhang G, Chen J
BMC Cancer. 2024; 24(1):1143.
PMID: 39272058
PMC: 11395217.
DOI: 10.1186/s12885-024-12892-5.
Combating bone marrow failure with polymer materials.
Koch K, Jadon N, Thesmar I, Tew G, Minter L
Front Immunol. 2024; 15:1396486.
PMID: 38694497
PMC: 11061490.
DOI: 10.3389/fimmu.2024.1396486.
A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.
Ptacin J, Ma L, Caffaro C, Acuff N, Germar K, Severy P
Commun Med (Lond). 2024; 4(1):58.
PMID: 38532017
PMC: 10966033.
DOI: 10.1038/s43856-024-00485-z.
LentiGlobin Administration to Sickle Cell Disease Patients: Effect on Serum Markers and Vaso-Occlusive Crisis.
Kumar H, Sharma V, Wadhwa S, Gowda D, Kaushik S, Joseph A
Cureus. 2024; 16(1):e51881.
PMID: 38327940
PMC: 10849583.
DOI: 10.7759/cureus.51881.
Improving the Therapeutic Potential of G-CSF through Compact Circular PEGylation Based on Orthogonal Conjugations.
Grigoletto A, Marotti V, Tedeschini T, Campara B, Marigo I, Ingangi V
Biomacromolecules. 2023; 24(9):4229-4239.
PMID: 37638739
PMC: 10498445.
DOI: 10.1021/acs.biomac.3c00543.
Effect of Granulocyte Colony-Stimulating Factor on the Development of Spermatogenesis in the Adulthood of Juvenile AML Mice Model Treated with Cytarabine.
Khaleel B, Lunenfeld E, Kapelushnik J, Huleihel M
Int J Mol Sci. 2023; 24(15).
PMID: 37569605
PMC: 10419160.
DOI: 10.3390/ijms241512229.
Assessing the Optimal Regimen: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Long-Acting Granulocyte Colony-Stimulating Factors in Patients with Breast Cancer.
You Z, Zhang H, Huang Y, Zhao L, Tu H, Zhang Y
Cancers (Basel). 2023; 15(14).
PMID: 37509336
PMC: 10378237.
DOI: 10.3390/cancers15143675.
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
Jiang Y, Zhang J, Zhong J, Liao H, Zhang J, Liu Y
BMC Cancer. 2023; 23(1):702.
PMID: 37495949
PMC: 10373237.
DOI: 10.1186/s12885-023-11198-2.
New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy.
Theyab A, Alsharif K, Alzahrani K, Oyouni A, Hawsawi Y, Algahtani M
Front Oncol. 2023; 12:1026377.
PMID: 36686781
PMC: 9850083.
DOI: 10.3389/fonc.2022.1026377.
Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study.
Wang Y, Zhao C, Ma P, Jiang D
Cancer Control. 2023; 30:10732748221140289.
PMID: 36598048
PMC: 9827532.
DOI: 10.1177/10732748221140289.
IgA nephropathy diagnosed as a result of acute exacerbation due to G-CSF administration.
Hattori K, Shimizu R, Tanaka S, Terashima T, Ishikawa R, Yamazaki M
CEN Case Rep. 2022; 12(3):270-274.
PMID: 36508113
PMC: 10393928.
DOI: 10.1007/s13730-022-00764-5.
A Poly-ADP-Ribose Polymer-GCSF Conjugate.
Cheng Q, Zhang X, Zhang L, Chen J, Wang Y, Zhang Y
Biomacromolecules. 2022; 23(12):5267-5272.
PMID: 36350184
PMC: 9772087.
DOI: 10.1021/acs.biomac.2c01090.
Comparison of Gene Editing versus a Neutrophil Elastase Inhibitor as Potential Therapies for Neutropenia.
Makaryan V, Kelley M, Fletcher B, Archibald I, Poulsen T, Dale D
J Cell Immunol. 2022; 4(1):19-28.
PMID: 36052149
PMC: 9431957.
DOI: 10.33696/immunology.4.129.
Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF).
Link H
Support Care Cancer. 2022; 30(9):7067-7077.
PMID: 35739328
PMC: 9225876.
DOI: 10.1007/s00520-022-07103-5.
A topological refactoring design strategy yields highly stable granulopoietic proteins.
Skokowa J, Hernandez Alvarez B, Coles M, Ritter M, Nasri M, Haaf J
Nat Commun. 2022; 13(1):2948.
PMID: 35618709
PMC: 9135769.
DOI: 10.1038/s41467-022-30157-2.
